GlassScriptPhysician profile
Auldyn F Hirschey
NPI 1114176914
$5,912.46
in general payments reported to CMS, 2019-2025
42 companies · $1,871 in 2025
The $1,871 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $203 · 2022: $755 · 2023: $1,717 · 2024: $1,366 · 2025: $1,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,808 · Long Term Medical Supply Or Device Loan: $2,115 · Education: $31.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.02 |
| Long Term Medical Supply Or Device Loan | $2,114.51 |
| Education | $31.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,433.93 | 2021-2025 | |
| Exelixis INC. | $1,188.12 | 2023 | Cabometyx |
| Celgene Corporation | $270.31 | 2022-2025 | Reblozyl, Pomalyst |
| Janssen Biotech, INC. | $263.53 | 2022-2025 | Rybrevant, Carvykti, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $158.50 | 2021-2022 | |
| Pfizer INC. | $148.37 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $133.78 | 2022-2025 | Keytruda, Welireg, Reblozyl |
| Array Biopharma INC | $106.88 | 2024-2025 | Mektovi, Lorbrena, Braftovi |
| Gilead Sciences, INC. | $103.40 | 2022-2025 | Trodelvy |
| Abbvie INC. | $82.83 | 2024-2025 | |
| Taiho Oncology, INC. | $81.36 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $67.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.97 | 2021-2025 | Sprycel |
| Pharmacyclics LLC, An Abbvie Company | $57.34 | 2022-2023 | Imbruvica |
| Blueprint Medicines Corporation | $56.43 | 2022-2023 | Ayvakit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Auldyn Hirschey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.